Colossal Biosciences, the US-based biotechnology firm known for its controversial yet ambitious 'de-extinction' projects, is reportedly in advanced talks to raise new capital that could see its valuation soar to between $20 billion and $30 billion (£15.5 billion - £23.3 billion). This potential funding round would represent a significant increase from its previous valuation of $10.2 billion (£8 billion) approximately 16 months ago, highlighting growing investor interest in the deep-tech sector.
The five-year-old company has garnered attention for its efforts to bring back species such as the woolly mammoth, dodo bird, and dire wolf using genetic material. While the specifics of the new funding round, including lead investors and the exact amount sought, remain undisclosed, reports suggest that Colossal has successfully begun generating revenue over the past year. This marks a pivotal shift for the startup, moving beyond pure research and development into commercialisation.
Colossal's co-founder and CEO, Ben Lamm, has previously outlined multiple revenue streams for the company. These include offering its advanced conservation technology to governmental bodies, with the UAE recently investing $60 million in the firm. Furthermore, Colossal has strategically spun out three independent startups: Breaking, which focuses on plastic degradation; Form Bio, a computational biology platform that secured $30 million in funding; and Astromech, an AI-driven predictive modelling company in life sciences, which was valued at $2 billion in March.
Looking ahead, Colossal also plans to commercialise its artificial animal womb technology, which Lamm suggests could have significant applications in human fertility treatment, with the technology expected to be ready next year. Should the company succeed in reintroducing extinct animals into their native habitats, it anticipates generating revenue through the sale of biodiversity credits. This market-based mechanism, similar to carbon credits, would reward conservation efforts and ecosystem restoration.
The reported fundraising efforts align with a broader surge in investment across deep-tech sectors, including longevity technology and alternative energy. For the UK, this trend underscores the global appetite for groundbreaking scientific innovation and the potential for new economic models rooted in biotechnology and environmental solutions. Regulatory bodies like the UK's Information Commissioner's Office (ICO) and the EU's forthcoming AI Act will undoubtedly monitor the ethical implications and data governance surrounding such advanced biological and AI-driven technologies, particularly as they approach human applications.
Experts suggest that while the 'de-extinction' concept remains contentious, the underlying genetic engineering, computational biology, and AI technologies being developed by Colossal Biosciences hold immense potential. These advancements could revolutionise fields from medicine and environmental conservation to materials science, offering both significant opportunities and complex ethical challenges that will require careful navigation by governments and industries worldwide.